Search results for "POINT"

showing 10 items of 4385 documents

GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in pati…

2019

Summary Background We previously showed that human anti-T-lymphocyte globulin (ATLG) plus ciclosporin and methotrexate given to patients with acute leukaemia in remission, having allogeneic haemopoietic stem-cell transplantation with peripheral blood stem cells from an HLA-identical sibling donor after myeloablative conditioning, significantly reduced 2-year chronic graft-versus-host disease (cGVHD) incidence and severity, without increasing disease relapse and infections, and improves cGVHD-free and relapse-free survival (cGRFS). The aim of an extended follow-up study was the assessment of long-term outcomes, which are, in this context, scarcely reported in the literature. We report unpubl…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentContext (language use)HematologyHematopoietic stem cell transplantationTotal body irradiation3. Good healthAnti-thymocyte globulinTransplantation03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicinemedicineClinical endpointCumulative incidencebusinessBusulfan030215 immunologymedicine.drugThe Lancet Haematology
researchProduct

Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization

2016

Abstract Objectives The study sought to investigate the impact of different computing methods for composite endpoints other than time-to-event (TTE) statistics in a large, multicenter registry of unprotected left main coronary artery (ULMCA) disease. Background TTE statistics for composite outcome measures used in ULMCA studies consider only the first event, and all the contributory outcomes are handled as if of equal importance. Methods The TTE, Andersen-Gill, win ratio (WR), competing risk, and weighted composite endpoint (WCE) computing methods were applied to ULMCA patients revascularized by percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) at 14 interna…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionInfarction030204 cardiovascular system & hematologymedicine.diseaseRevascularization03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineConventional PCIPost-hoc analysismedicineClinical endpointCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Interventions
researchProduct

Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing

2020

Abstract Background Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy. Methods A multicenter retrospective study was performed in Italy (June 2016–June 2019). Successful clinical outcome was defined as complete resolution of clinical signs/symptoms related to ESBL-E infection and lack of microbiological evidence of infection. The primary end point was to identify predictors of clinical failure of C/T therapy. Results C/T treatment was documented in 153 patients: pneumonia was the most common diagnosis (n = 46…

medicine.medical_specialtyceftolozane/tazobactammedicine.medical_treatmentCRRTTazobactamEnterobacteralesEnterobacteraleInternal medicineCRRT; ESBL; Enterobacterales; ceftolozane/tazobactam; septic shockMajor ArticlemedicineClinical endpointRenal replacement therapybusiness.industrySeptic shockRetrospective cohort studyOdds ratiomedicine.diseaseCeftolozane/tazobactam; CRRT; Enterobacterales; ESBL; Septic shockAcademicSubjects/MED00290Infectious DiseasesOncologyESBLseptic shockCeftolozanebusinessEmpiric therapymedicine.drugOpen forum infectious diseases
researchProduct

Sentinel-node biopsy in early stage ovarian cancer: a prospective multicentre study (SELLY)

2019

BackgroundSystematic para-aortic and bilateral pelvic lymphadenectomy is included in the standard comprehensive surgical staging in presumed early epithelial ovarian cancer. No prospective randomized evidence suggests it has potential therapeutic value, and related morbidity is not negligible.Primary Objective(s)To assess sensitivity, safety, and feasibility of the sentinel lymph node technique in identifying the presence of lymph node metastases in patients with early stage epithelial ovarian cancer.Study HypothesisSentinel lymph node detection with indocyanine green can accurately predict nodal status in a cohort of women with early stage epithelial ovarian cancer.Trial DesignThe SELLY tr…

medicine.medical_specialtyearly ovarian cancermedicine.medical_treatmentearly ovarian cancer; indocyanine green (ICG); laparoscopy; lymphadenectomy; minimally-invasive surgery; sentinel node; Carcinoma Ovarian Epithelial; Cohort Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Neoplasm Staging; Ovarian Neoplasms; Prospective Studies; Sensitivity and Specificity; Sentinel Lymph Node; Sentinel Lymph Node BiopsySentinel lymph nodelaparoscopyCarcinoma Ovarian EpithelialSensitivity and SpecificityCohort Studiesindocyanine green (ICG)Ovarian EpithelialBiopsymedicineClinical endpointHumansProspective StudiesStage (cooking)Lymph nodeNeoplasm StagingOvarian Neoplasmsmedicine.diagnostic_testbusiness.industrySentinel Lymph Node BiopsyCarcinomaObstetrics and GynecologySentinel nodemedicine.diseaseearly ovarian cancer; indocyanine green (ICG); laparoscopy; lymphadenectomy; minimally-invasive surgery; sentinel nodeminimally-invasive surgerymedicine.anatomical_structureSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologysentinel nodeLymphatic MetastasislymphadenectomyLymphadenectomyFemaleRadiologyLymph NodesSentinel Lymph NodebusinessOvarian cancer
researchProduct

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve …

2011

Summary.  In chronic hepatitis C (CHC), treatment duration may be individualized according to time to first undetectable hepatitis C virus (HCV) RNA, with patients who attain undetectable HCV RNA early in treatment being candidates for shorter regimens. The aim of this study was to determine the relapse rate in patients with CHC genotype (G) 1 infection and low baseline viral load who achieved undetectable HCV RNA by week 4 [rapid virologic response (RVR)] when treated for 24 weeks. This was an open-label, multicentre, noninterventional study. Adult patients with G1 CHC infection and baseline viral load <600,000 IU/mL who attained RVR were treated with peginterferon alfa-2b (1.5 μg/kg/week)…

medicine.medical_specialtyeducation.field_of_studyHepatologybusiness.industryRibavirinHepatitis C virusPopulationvirus diseasesmedicine.disease_causeGastroenterologychemistry.chemical_compoundInfectious DiseaseschemistryVirologyInternal medicineImmunologymedicineClinical endpointPeginterferon alfa-2bRapid Virologic ResponseeducationbusinessAdverse effectViral loadmedicine.drugJournal of Viral Hepatitis
researchProduct

Recognition and characterization of small colonic neoplasia with high-definition colonoscopy using i-Scan is as precise as chromoendoscopy

2010

Abstract Background The EPKi system (Pentax, Japan) enables resolution above HDTV. Aim of the study was to test the efficacy of HD+ alone and with the new post-processing digital filter i-Scan or chromoendoscopy (Methylene blue 0.1%) in screening for colorectal cancer. We focused on lesions less than 5 mm as a surrogate marker for the optical possibilities of the EPKi system. Methods The last 30 cm of the colon in a screening population were inspected with HD+ alone, in combination with i-Scan (2:1 randomisation) and subsequently with chromoendoscopy. All lesions were characterized and targeted biopsies were performed. Results i-Scan augmented in 69 patients the identification of lesions fr…

medicine.medical_specialtyeducation.field_of_studyHepatologymedicine.diagnostic_testColorectal cancerSurrogate endpointbusiness.industryHigh definition endoscopyPopulationGastroenterologyColonoscopymedicine.diseaseTime efficientChromoendoscopymedicineHigh definitionRadiologyeducationbusinessDigestive and Liver Disease
researchProduct

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-labe…

2013

Summary Background Patients with advanced gastric cancer have a poor prognosis and few efficacious treatment options. We aimed to assess the addition of cetuximab to capecitabine-cisplatin chemotherapy in patients with advanced gastric or gastro-oesophageal junction cancer. Methods In our open-label, randomised phase 3 trial (EXPAND), we enrolled adults aged 18 years or older with histologically confirmed locally advanced unresectable (M0) or metastatic (M1) adenocarcinoma of the stomach or gastro-oesophageal junction. We enrolled patients at 164 sites (teaching hospitals and clinics) in 25 countries, and randomly assigned eligible participants (1:1) to receive first-line chemotherapy with …

medicine.medical_specialtyeducation.field_of_studyIntention-to-treat analysisCetuximabbusiness.industryPopulationMedizinRashSurgeryRamucirumabCapecitabineRegimenOncologyInternal medicineClinical endpointMedicinemedicine.symptombusinesseducationmedicine.drugThe Lancet Oncology
researchProduct

Subclinical atherosclerosis: independent predictor of cardiovascular events in a 20-years follow up of patients with or without metabolic syndrome

2013

Purpose: To evaluate the influence of carotid atherosclerosis and metabolic syndrome (MetS) on the prediction of cardiovascular events during a 20-years follow-up. Methods: We studied a population of 529 asymptomatic patients, divided into 2 groups according to the results of the carotid ultrasound evaluation: one without atherosclerotic lesions (198 patients) and a second one with an increased carotid IMT or asymptomatic carotid plaque (331 patients). In each of these groups, we identified two subgroups of subjects with and without MetS. Cardiovascular endpoints were investigated in a 20-years follow-up: acute myocardial infarction, angina, transient ischemic attack, ischemic stroke, abdom…

medicine.medical_specialtyeducation.field_of_studybusiness.industrySurrogate endpointmedicine.medical_treatmentPopulationmedicine.diseaseAsymptomaticAbdominal aortic aneurysmAnginaAtherectomyInternal medicinemedicineCardiologyMyocardial infarctionmedicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinesseducationEuropean Heart Journal
researchProduct

Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

1994

We have analysed 118 families with inherited medullary thyroid carcinoma (MTC) for mutations of the RET proto-oncogene. These included cases of multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) and familial MTC (FMTC). Mutations at one of 5 cysteines in the extracellular domain were found in 97% of patients with MEN 2A and 86% with FMTC but not in MEN 2B patients or normal controls. 84% of the MEN2A mutations affected codon 634. MEN 2A patients with a Cys634 to Arg substitution had a greater risk of developing parathyroid disease than those with other codon 634 mutations. Our data show a strong correlation between disease phenotype and the nature and position of the RET mutatio…

medicine.medical_specialtyendocrine system diseasesOncogene RETDNA Mutational AnalysisMolecular Sequence DataMultiple endocrine neoplasia type 2RET proto-oncogeneBiologymedicine.disease_causeProto-Oncogene MasInternal medicineProto-Oncogene ProteinsProto-OncogenesGeneticsmedicineDrosophila ProteinsHumansPoint MutationThyroid NeoplasmsMultiple endocrine neoplasiaDNA PrimersMutationBase SequencePoint mutationMultiple Endocrine NeoplasiaProto-Oncogene Proteins c-retReceptor Protein-Tyrosine KinasesExonsmedicine.diseasePhenotypeEndocrinologyPhenotypeProto-Oncogene Proteins c-retCarcinoma MedullaryCancer researchNature genetics
researchProduct

Effects of empagliflozin on CA125 trajectory in patients with chronic congestive heart failure

2021

INTRODUCTION: We aimed to evaluate the trajectory of two surrogates of fluid overload -antigen carbohydrate 125 (CA125) and amino-terminal pro-brain natriuretic peptide (NT-proBNP)- after the addition of oral empagliflozin to usual care in a cohort of patients with chronic heart failure (CHF) and type 2 diabetes (T2D). METHODS AND RESULTS: From October 2015 to February 2019, 60 ambulatory patients with CHF and T2D were retrospectively included. The primary endpoint was to assess the longitudinal trajectory of plasma levels of CA125 and NT-proBNP after empagliflozin initiation. Changes in quantitative variables were evaluated using linear mixed regression. Median CA125 and NT-proBNP at basel…

medicine.medical_specialtyendocrine system diseasesType 2 diabetes030204 cardiovascular system & hematologyCA12503 medical and health sciences0302 clinical medicineGlucosidesEmplagliflozinInterquartile rangeLongitudinal trajectoriesInternal medicineNatriuretic Peptide BrainmedicineEmpagliflozinClinical endpointHumansSGLT2icardiovascular diseases030212 general & internal medicineBenzhydryl CompoundsRetrospective StudiesHeart FailureSurrogate endpointbusiness.industrymedicine.diseasePeptide FragmentsDiabetes Mellitus Type 2Heart failureNTproBNPAmbulatoryCohortCardiologyCardiology and Cardiovascular MedicinebusinessBiomarkersInternational Journal of Cardiology
researchProduct